Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a legal strategy. In practice, it’s an engineering discipline—one that starts with reading formulation …
Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …
Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”?
At first glance, the two sound like cousins—both extend exclusivity, both protect revenue, both buy time. But in practice, the…
Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…
Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
If you’re building a Eurasia strategy—whether for market entry, lifecycle management, or portfolio protection—this is the part that…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Pharmaceutical patent strategy is often discussed like a courtroom drama: file early, argue hard, win big.
But the real cost isn’t just legal fees—it’s the opportunity cost of building portfolios that look impressive on paper and fail in practice.
In a…
The clock is ticking—so why are so many commercial market access teams waiting until after the patent clock runs out?
In pharma, timing isn’t just strategy—it’s survival.
A lot of business development (BD) in commercial market access still behaves like…
Before You Launch: The Freedom-to-Operate Checklist Pharma Teams Wish They Had Earlier
Launching a drug is a sprint disguised as a marathon. The science is hard, the manufacturing is harder, and the regulatory work is relentless. But there’s one risk t…
Most pharma buyers treat Paragraph IV diligence like paperwork. That’s why they get burned.
Paragraph IV filings are supposed to be a warning system. A signal that a generic manufacturer may challenge a brand’s patent protections—and that the commercia…
Paragraph IV Filings: The Procurement Due Diligence Tool Most Pharma Buyers Ignore Read Post »
Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re building a pipeline, underwriting a deal, or forecasting exclusivity value in Asia-Pacific, here’s the uncomfortable truth: “patent term” is n…
Get new actionable insights and updates from BiotechBlog
